Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to 3.97%.

  • International Stem Cell's EBIT Margin rose 81000.0% to 3.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 74000.0%. This contributed to the annual value of 0.75% for FY2024, which is 77600.0% up from last year.
  • As of Q3 2025, International Stem Cell's EBIT Margin stood at 3.97%, which was up 81000.0% from 6.82% recorded in Q2 2025.
  • International Stem Cell's EBIT Margin's 5-year high stood at 6.82% during Q2 2025, with a 5-year trough of 34.2% in Q1 2021.
  • Its 5-year average for EBIT Margin is 8.34%, with a median of 4.92% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 354400bps in 2022, then crashed by -249600bps in 2023.
  • Quarter analysis of 5 years shows International Stem Cell's EBIT Margin stood at 17.53% in 2021, then soared by 114bps to 2.51% in 2022, then plummeted by -994bps to 22.45% in 2023, then skyrocketed by 109bps to 2.09% in 2024, then soared by 90bps to 3.97% in 2025.
  • Its EBIT Margin stands at 3.97% for Q3 2025, versus 6.82% for Q2 2025 and 10.1% for Q1 2025.